Phibro Animal Health (NASDAQ:PAHC – Get Rating) was downgraded by StockNews.com from a “strong buy” rating to a “buy” rating in a report on Friday.
A number of other research companies have also weighed in on PAHCs. Barclays upgraded shares of Phibro Animal Health from an “underweight” rating to an “equal weight” rating and set a target price of $23.00 on the stock in a Monday, January 10 report. Morgan Stanley began covering shares of Phibro Animal Health in a report on Thursday, November 18. They issued an “equal weight” rating and target price of $23.00 on the stock.
NASDAQ PAHC shares opened at $20.41 on Friday. The company has a current ratio of 3.05, a quick ratio of 1.67 and a debt ratio of 1.62. Phibro Animal Health has a 1 year minimum of $18.24 and a 1 year maximum of $31.00. The company has a market capitalization of $826.69 million, a P/E ratio of 15.58 and a beta of 0.53. The company’s 50-day moving average price is $20.32 and its 200-day moving average price is $21.27.
Phibro Animal Health (NASDAQ:PAHC – Get Rating) last reported results on Wednesday, February 9. The company reported earnings per share of $0.37 for the quarter, beating the Zacks consensus estimate of $0.33 by $0.04. Phibro Animal Health achieved a net margin of 6.06% and a return on equity of 22.44%. During the same period last year, the company posted EPS of $0.33. Equity research analysts expect Phibro Animal Health to post EPS of 1.38 for the current year.
Hedge funds have recently changed their stakes in the company. Louisiana State Employees Retirement System increased its position in Phibro Animal Health by 6.5% in Q3. Louisiana State Employees Retirement System now owns 9,800 shares of the company worth $211,000 after purchasing an additional 600 shares last quarter. Amalgamated Bank bought a new position in shares of Phibro Animal Health during Q2, valued at approximately $319,000. GSA Capital Partners LLP increased its position in shares of Phibro Animal Health by 103.3% during the 3rd quarter. GSA Capital Partners LLP now owns 40,250 shares of the company valued at $867,000 after acquiring an additional 20,454 shares during the period. Invesco Ltd. increased its position in shares of Phibro Animal Health by 185.0% during the 2nd quarter. Invesco Ltd. now owns 475,067 shares of the company valued at $13,721,000 after acquiring an additional 308,372 shares during the period. Finally, First Hawaiian Bank increased its position in shares of Phibro Animal Health by 5.8% in the 3rd quarter. First Hawaiian Bank now owns 11,895 shares of the company valued at $256,000 after acquiring an additional 657 shares during the period. 51.47% of the shares are held by institutional investors and hedge funds.
Company Profile Phibro Animal Health (Get a rating)
Phibro Animal Health Corp. is engaged in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops and markets antibacterial products, nutritional specialties and vaccines.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Phibro Animal Health right now?
Before you consider Phibro Animal Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Phibro Animal Health didn’t make the list.
Although Phibro Animal Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here